anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
FIELD: food industry. ^ SUBSTANCE: invention refers to food composition for infants. The food composition consists of a) non-digestible fermented partially hydrolysed gum with a degree of polymerisation between 10 and 300 at amount from 0.1 to 15 g per 100 g of dry weight of composition. Also the composition consists of b) non-digestible fermented soluble polysaccharide with a degree of polymerisation between 10 and 300, different, than partially hydrolysed gum, at amount from 0.1 to 15 g per 100 g of dry weight of the said composition. Notably, weight ratio of a) : b) is between 19:1 and 1:19. Caloric value of the composition is from 50 to 200 kcal/100 ml upon reduction of it to a liquid form. Additionally, protein composes from 5 to 16% of total caloric value, fat - from 35 to 60%, while carbohydrates - from 25 to 75%. ^ EFFECT: facilitating production of synergetic composition for feeding infants which is used in method of treatment and/or prevention of inflammatory diseases of bowels and/or syndrome of irritated bowels of infants. ^ 15 cl, 1 dwg, 2 tbl, 4 ex
The present invention provides a device and a method for automatically detecting a 3D cephalometric landmark using computerized tomography (CT), the device comprising: a binarizing unit; a basic landmark obtaining unit; a landmark schematic estimating unit; and a landmark precision estimating unit. The binarizing unit receives a 3D head CT image by photographing a head of a subject, and obtains a binarizing CT image by binarizing a pixel value of the 3D head CT image depending on a predetermined threshold value. The basic landmark obtaining unit detects the predetermined number of cephalometric landmarks existing at designated positions which are easy to be detected depending on geometric characteristics as a basic landmark among the number of cephalometric landmarks showing feature positions in the head in the binarizing CT image by using a pre-trained artificial neural network. The landmark schematic estimating unit obtains a plurality of schematic landmarks by individually estimating the total cephalometric landmarks represented by a position coordinate vector on the binarizing CT image from the predetermined number of basic landmarks by using the pre-trained artificial neural network. The landmark precision estimating unit divides the binarizing CT image into a lower jaw image for a lower jawbone and a cranial image for a cranial bone depending on a predetermined method; and obtains a precise cephalometric landmark by dividing the plurality of schematic landmarks into a plurality of lower jaw schematic landmarks and a plurality of cranial schematic landmarks and re-estimating positions corresponding to the divided lower jaw image and the cranial image. Provided are the device and the method for automatically detecting a 3D cephalometric landmark capable of detecting an accurate 3D cephalometric landmark with a small amount of training data.
Methods are provided relating to the enhanced cytoplasmic accumulation of amphipathic weakly basic or amphipathic cationic molecules in prokaryotes and eukaryotes under conditions of high extracellular pH. Furthermore, the methods relate to the unexpected synergistic effects of high extracellular pH and disrupted cellular efflux mechanisms on the cytoplasmic accumulation of amphipathic weakly basic or amphipathic cationic molecules in prokaryotes and eukaryotes. Methods are also provided for increasing the therapeutic potency of amphipathic weakly basic or amphipathic cationic compounds, e.g. antiseptics and disinfectants by using the antiseptic or disinfectant in the presence of a multiple drug resistance inhibitor such as reserpine. Finally, methods also relate to the exploitation of the aforementioned discoveries in the screening of small molecules, and libraries thereof, for biological activity in prokaryotes and eukaryotes. Also provided is a formulation comprising an amphipathic weak base, an amphipathic cation, or both, and a multiple drug resistance inhibitor wherein the pH of the formulation is 9.0. Furthermore, the combination of these ingredients have antiseptic and/or disinfectant effects.
Combining the StandUPTV application with personalized action plans to enhance the maintenance of reduced eSST. At baseline, participants will receive Action Planning Education, action planning worksheet, and weekly personalized text messages reinforcing the action plan. Participant will then receive a daily StandUPTV alert after performing 30 minutes of eSST, and they have 60 minutes after the alert to engage in their active chosen non-sedentary behavior. Financial Incentives: Participants can earn up to $30 per month during the 4-month intervention by starting 10 minutes of their non-sedentary replacement behavior within 60 minutes of the alert. Participants start with $30 in their account and lose $2 for each day they do not perform the behavior. Notifications will be sent via SMS and the StandUPTV app.
BACKGROUND: Dystonia is a hyperkinetic movement disorder that results in twisting, cramps and tremors due to sustained or intermittent muscle contractions. Cervical dystonia is the most common form of dystonia, in which the head, neck and/or shoulder areas are affected. In addition to these motor symptoms, pain and psychiatric symptoms are frequent in (cervical) dystonia.
OBJECTIVE: Description of the incidence and evaluation of pain in cervical dystonia, summary and discussion of treatment options and effects.
MATERIAL AND METHODS: In this review article the results in the scientific literature on pain in dystonia are summarized and discussed.
RESULTS: Compared to other forms of dystonia, pain occurs most frequently in patients with cervical dystonia. A large proportion of patients with cervical dystonia suffer from pain, which contributes most to impairment of the patient. The motor symptoms of dystonia are usually treated with botulinum toxin injections. These have a muscle relaxing effect and also relieve pain. The study situation on the occurrence and treatment of pain in other forms of dystonia is so far very limited. Pain can dominate the clinical picture in patients with cervical dystonia. Evaluation of pain in cervical dystonia can be performed using standardized questionnaires.
CONCLUSION: It is important to ask patients with cervical dystonia about pain and to consider it in treatment planning and evaluation. Vice versa, if pain is present the possibility of a causative dystonia should also be considered. For pain assessment there are some newly developed questionnaires to assess pain in a standardized way in patients with dystonia. Further research is needed to better understand the pathomechanisms of pain in dystonia.
Hypertrophic cardiomyopathy (HCM) is an inherited heart muscle disease that is characterised by left ventricular wall thickening, cardiomyocyte disarray and fibrosis, and is associated with arrhythmias, heart failure and sudden death. However, it is unclear to what extent the electrophysiological disturbances that lead to sudden death occur secondary to structural changes in the myocardium or as a result of HCM cardiomyocyte electrophysiology. In this study, we used an induced pluripotent stem cell model of the R403Q variant in myosin heavy chain 7 (MYH7) to study the electrophysiology of HCM cardiomyocytes in electrically coupled syncytia, revealing significant conduction slowing and increased spatial dispersion of repolarisation - both well-established substrates for arrhythmia. Analysis of rhythmonome protein expression in MYH7 R403Q cardiomyocytes showed reduced expression of connexin-43 (also known as GJA1), sodium channels and inward rectifier potassium channels - a three-way hit that reduces electrotonic coupling and slows cardiac conduction. Our data represent a previously unreported, biophysical basis for arrhythmia in HCM that is intrinsic to cardiomyocyte electrophysiology. Later in the progression of the disease, these proarrhythmic phenotypes may be accentuated by myocyte disarray and fibrosis to contribute to sudden death.
This study, which was planned as an experimental study with a pretest-posttest control group, will be a study for patients who will undergo coronary angiography in the angiography unit of Fırat University Hospital and Fethi Sekin City Hospital. Prior to the study, a priori power analysis was performed to determine the sample size in this study. In the power analysis, it was determined that a total of at least 120 samples, including 1st Group 30, 2nd Group 30, 3rd Group 30 and control group 30, should be at 0.05 significance level, 95% confidence interval, 95% power and 5% margin of error. Random numbers table will be used to determine the experimental and control groups. Then, by drawing lots, 1.2.3. experimental group and control group will be assigned. The patients in the experimental group will be divided into three as those who will be treated only with music, who will be treated with aromatherapy only through inhalation, and those who will be treated with music and inhalation aromatherapy together. Before any intervention is made in the intervention group and control group, the Patient Information Form, Visual Analog Scale-Pain (VAS-P), Visual Analog Scale-Fear (VAS-F), Visual Analog Scale was given to the patients to determine the pain, anxiety and fear level of these patients. -Anxiety (VAS-A), State-Trait Anxiety Inventory (DSÖ) will be used to pre-test. Inhaler aromatherapy, music concert, music concert and inhaler aromatherapy applications will be applied to the patients in the intervention groups before and during the procedure, while the control group will not receive any intervention. With the post-test, VAS-P, VAS-F, VAS-A, DSÖ will be applied to both the intervention and control groups and their pain, anxiety and fear levels will be evaluated. Finally, it will be checked whether there is a significant difference between the pre-test and post-test.
The hypothesis of the trial is that during the perioperative period serious fluctuations outside the recommended target depth of anaesthesia could occur. These fluctuations and the cumulative time spent in the shallow (over 60 BIS) or deep (under 40 BIS) could be associated with postoperative complications like emergence delirium (PAED over 10, and PAED over 12- 2 measurement methods), postoperative nausea and vomiting (PONV) and other postoperative complications (respiratory, hemodynamic).

Paediatric patients (between 1 year -19 years) undergoing elective general anaesthesia with presumed duration over 1 hour will be eligible for inclusion. The patients will be screened for eligibility during the preanaesthesia visit in the anaesthesiology examination room. After the Ethics committee and registration of the study at clinicaltrials.gov, the patients will be enrolled - according to the trial design. There is a presumption that informed consent won't be needed for participation due to observational trial. The anaesthesia induction will be performed either inhalation or intravenous route. After anaesthesia induction BIS monitor will be placed on the forehead according to the manufacturer recommendation and the anaesthesia team will be blinded to BIS monitor during the whole case. The initial BIS tracing will be recorded starting the surgery initiation (defined as the depth of anesthesia by the anaesthesiologist to initiate surgical intervention) and ending with end of surgical intervention. The incidence of periods outside the recommended anaesthesia depth will be recorded (episode is defined by ≥ 30 seconds interval outside the predefined limits, the end of episode is defined by the return to recommended BIS level). The cumulative time spent outside the recommended BIS levels will be evaluated as the primary outcome measure. The anaesthesiologist's ability to respond to fluctuations defined as YES / NO response, type of intervention and latency of the anaesthesiologist's response to fluctuation will be evaluated. The BIS recording will be terminated at the time the surgical intervention is finished. After surgery/anaesthesia, the patient will be transferred to ICU or post-anaesthesia care unit (PACU), where the incidence of emergence delirium (defined by PEAD score over 10 and over 12 - according to 2 measurement methods) and the incidence of PONV will be recorded. Also, cumulative incidence of overall complication in the postoperative period (desaturation, the need for oxygen therapy, haemodynamic instability, arrhythmias (over 150/min, below 50/min, allergic reactions) will be recorded. In the case of a critical BIS value (≥90, ≤10), blinding will be interrupted due to patient safety and the value will be notified to the anesthesiology team and the event will be recorded as a critical event.
Adrenocortical carcinoma(ACC)is a rare malignancy with an incidence of 1.5 to 2 per million per year in the United states. Surgery is the only therapeutic option that can prolong survival. Currently there are no therapies that have been proven to prolong survival for patients with nonsurgically resectable disease. ACC has been shown to be highly resistant to standard chemotherapy, therefore, it is important that we test agents with mechanisms of action. This is a single arm phase II study of Bevacizumab, an angiogenesis inhibitor, given as a single agent at 10 mg/kg IV every 2 weeks in patients with unresectable ACC. Bevicizumab will be used as first line therapy. The study will test if Bevacizumab will be able to prolong the time to progression. If a delay in time to progression of 4 months or greater is seen, this will be considered clinically meaningful and further studies will be considered. This study will be conducted at multiple institutions (see below).
Ectopic varices account for 5% of variceal bleedings and occur outside the gastro-esophageal region. This review evaluates the efficacy of transjugular intrahepatic portosystemic shunt (TIPS) for ectopic variceal management. A comprehensive search through PubMed, Scopus, Web of Science, and Embase was conducted until January 16, 2023, using relevant keywords. Case reports and case series with fewer than 10 patients on TIPS for ectopic variceal management were included. The quality assessment followed the Joanna Briggs Institute checklist for case reports. This systematic review evaluated 43 studies involving 50 patients with ectopic varices undergoing TIPS. Patients had a mean age of 54.3 years, half were female, and two were pregnant. Alcoholic liver disease (48%) and hepatitis C infection (26%) were common causes of portal hypertension. Ascites and splenomegaly were reported in 32% and 28% of the patients, respectively. Rectal, oral, and stomal variceal bleeding accounted for 62%, 16%, and 22% of the patients, respectively. Ectopic varices were mainly located in the duodenum (28%) and rectum (26%) regions. Complications affected 42% of the patients, re-bleeding in eleven and hepatic encephalopathy in seven. The follow-up lasted 12 months on average, and finally, 5 received a liver transplant. Mortality post-TIPS was 18%. Despite complications and a notable mortality rate, favorable outcomes were observed in almost half of the patients with ectopic variceal bleeding managed with TIPS. Further research is warranted to refine strategies and improve patient outcomes.
Propofol will be administered in bolus doses of 0.5mg/kg. Doses will be determined according to the clinical condition of the patient.
A 4-month-old full-term female presented with growth faltering associated with progressive feeding difficulty, rash, abdominal distension, and developmental delays. She was found to have disconjugate gaze, abnormal visual tracking, mixed tone, bruising, and splenomegaly on examination. Initial workup was notable for thrombocytopenia and positive cytomegalovirus (CMV) immunoglobulin G and immunoglobulin M antibodies. She initially presented to the infectious diseases CMV clinic, where she was noted to have severe malnutrition, prompting referral to the emergency department for hospital admission to optimize nutrition with nasogastric tube feeding and facilitate additional evaluation. An active CMV infection with viruria and viremia was confirmed, but elements of her presentation and workup including brain magnetic resonance imaging were not consistent with isolated CMV infection. To avoid premature diagnostic closure, a multidisciplinary workup was initiated and ultimately established her diagnosis.
PURPOSE: To investigate the effect of Morinda officinalis polysaccharides(MOP) on the expression of fibronectin(FN) and fibronectin containing extra domain A(FN-EDA) in inflammatory periodontal ligament fibroblasts.
METHODS: Thirty six rats were randomly divided into a control group(n=12) and a model group (n=24). The model group used orthodontic wire ligation to establish periodontitis. After three weeks, 6 rats from each group were selected and confirmed by Micro-CT to complete the modeling. The remaining rats in the model group were randomly divided into periodontitis group, normal saline(NS) group, and MOP group. In the MOP group, MOP (200 mg/kg for 3 d, 50 μL for 4 weeks) was injected into the palatal side of the left maxillary first molar of the rats. In the NS group, same volume of NS was injected, and no treatment was performed in the periodontitis group. The left maxillary tissue of rats were taken and the pathological changes of periodontal tissue were observed by H-E staining. The expression of FN and FN-EDA was detected by immunohistochemistry. Periodontal ligament fibroblasts were cultured in vitro, the effect of MOP on cell activity detected by CCK-8. The fourth generation cells were divided into control group, inflammation group (10 mg/mL lipopolysaccharide), and experimental group (12.5 μg/mL MOP, 12.5 μg/mL MOP+10 mg/mL lipopolysaccharide). The expression of FN and FN-EDA was detected by qRT-PCR and Western blot. The data were statistically analyzed using Prism 8.0 software package.
RESULTS: In vivo experiments, the expression of FN-EDA in the MOP group was significantly lower than that in the periodontitis group and NS group(P<0.05), and the infiltration of inflammatory cells was reduced. However, there was no significant difference in the expression of FN in each group. In vitro experiments, compared with the control group, the expression of FN-EDA mRNA and protein in the inflammation group was significantly increased(P<0.000 1). MOP significantly reduced the expression of FN-EDA in inflammatory cells, but had no significant effect on FN expression.
CONCLUSIONS: With increased expression of FN-EDA in inflammatory periodontal ligament tissues and cells, MOP may play a role in inhibiting inflammation by down-regulating FN-EDA.
A composition for facilitating the bone lengthening growth by using the hot water extract of Lentinus edodes is provided to increase the expression of IGF-1(Insulin-like growth factor 1) and/or the growth hormone, so that the composition is useful for prevention and treatment of the bone lengthening growth disorder. The composition for promotion of the bone lengthening growth and for prevention and treatment of the bone lengthening growth disorder comprises the hot water extract of Lentinus edodes which is prepared by slicing the Lentinus edodes and extracting the sliced Lentinus edodes in distilled water at 100-120 deg. C for 4 hours with flux cooling, evaporating the hot water extract of Lentinus edodes at 750mmHg and 35-55 deg. C, and freeze-drying the evaporated hot water extract of Lentinus edodes at -20 deg. C and -80 deg. C sequentially for 48 hours, and is formulated as fermented milk, beverage or health food.
Subjects applied PBM(Color-DNA-WSF U, Color Seven; 610 nm±10nm wavelength; 3.0 mW/㎠±20%) therapy in the locations of the sternocleidomastoid muscle in the ICA area and the trapezius muscle in VA area. PBM was applied 5 times a week for 8 weeks, 30 minutes per session.
To provide software for the purpose of reduction of primary works at a medical institution, medicine prescription input and receipt creating works.SOLUTION: Input fields of medical data are eliminated as much as possible. A medical product, a dosage, and the number of days are extracted from data input like a word-processor scheme. Points of the medical product and the number of medicines are calculated for the unit of prescription. Moreover, the kind of a receipt for a patient is automatically determined, and a process of creating prescription source data to create a prescription is executed within several hundred milliseconds. Processes including creation of receipt source data day by day and an electronic receipt month by month can be executed (FIG. 5).SELECTED DRAWING: Figure 5
The aim of the study is to in-vitro characterize and expand T cells specific for melanoma-derived antigens. Peripheral blood with be collected from 20 volunteers with biopsy proven melanoma and 10 age matched controls. Blood will be collected prior to the initiation of chemotherapy. There will be no more than two blood draws per patient. Most patients will receive a single blood draw; however, some participants may be asked to return for a single additional blood draw if investigators were unable to isolate melanoma-specific immune cells after the first blood draw. Two separate blood draws will be the maximum. The interval between these blood draws will be a minimum of 3 months apart. Blood samples will be used to determine the patient's HLA haplotype via PCR and DNA sequencing. After the patient's haplotype has been established melanoma-specific T cell clones will be generated from the peripheral blood samples and expanded in-vitro. These clones will then be assayed for specificity against commercially available melanoma cell lines. The T cell clones will also be assayed for reactivity to melanocyte differentiation antigens such as MART-1 and gp100. If the volunteer requires a palliative resection of a melanoma tumor then the patient's own tumor cells may also be used to test the specificity of the isolated T cell clones. All experiments will be conducted in-vitro.
An initial dose of 180 µg of Igalmi as needed for the treatment of agitation over a period of 7 days. In the event of persistent or recurrent agitation, investigators may choose to repeat dose at 90 μg after the 2-hour time point in the absence of dose-limiting adverse events or safety concerns. A maximum of 2 repeat doses will be allowed in a 24-hour period.
The invention discloses a stilbene compound separated from Lhasa rhubarb and an application thereof in treating nervous system diseases. The invention separates three new stilbenes compounds from the rhubarb of Lhasa, the structural formula of which is shown as formula I, formula II or formula III. The invention further discloses a method for separating and obtaining a stilbene compound from the Rheum lasagni. The result of in vitro determination of the inhibitory activity of the compound on acetylcholinesterase shows that the compound has stronger inhibitory effect on acetylcholinesterase. The invention further carries out animal experiments and behavioral experiments NOR, MWM, PAT, cholinergic detection, oxidative stress detection and the like on the compound shown in the formula I to evaluate the improvement effect of the compound shown in the formula I on the cognitive disorder induced by the scopolamine, and the experimental result shows that the compound shown in the formula I can obviously improve the cognitive disorder induced by the experimental animals on the scopolamine. The stilbene compound provided by the invention can be used for preparing a medicament for treating neurodegenerative diseases.